In this issue:
- Neoadjuvant-adjuvant vs. adjuvant pembrolizumab in advanced melanoma
- Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma
- 7-year analysis of adjuvant pembrolizumab for resected stage III melanoma
- Adjuvant dabrafenib trametinib for stage III melanoma: final results
- 5-year outcomes with dabrafenib-trametinib in metastatic melanoma
- Factors influencing use of shave biopsy for melanoma suspicious lesions
- Breslow density for predicting melanoma survival
- Residual BCC after excision
- Mohs surgery vs. wide local excision for primary high-stage SCC
- Superficial curettage then imiquimod vs. surgical excision for nodular BCC
Please login below to download this issue (PDF)